Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1945229 | 0.91 | PIK3CG (0.71) | FYNPIK3CG | |
| SCHEMBL1946247 | 0.86 | FYN (0.71) | FYNPIK3CG | |
| SCHEMBL1650487 | 0.83 | FYN (0.82) | FYN | |
| SCHEMBL1945215 | 0.83 | FYN (0.80) | FYN | |
| SCHEMBL1945969 | 0.83 | FYN (0.72) | FYN | |
| SCHEMBL1944386 | 0.82 | FYN (0.72) | FYN | |
| SCHEMBL1052939 | 0.81 | PIK3CG (0.86) | FYNPIK3CG | |
| SCHEMBL1944389 | 0.81 | FYN (0.73) | FYNPIK3CG | |
| SCHEMBL1946935 | 0.81 | FYN (0.68) | FYN | |
| SCHEMBL1651947 | 0.81 | FYN (0.67) | FYNPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2307425-B1 | IMIDAZOTHIADIAZOLES DERIVATIVES | MERCK PATENT GMBH (DE) | 2014-03-26 | — | — | EP | claimed |
| EP-2307425-B1 | IMIDAZOTHIADIAZOLES DERIVATIVES | MERCK PATENT GMBH (DE) | 2014-03-26 | — | — | EP | disclosed |
| US-8389554-B2 | Imidazothiadiazole derivatives | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 2013-03-05 | — | — | US | disclosed |
| US-8389554-B2 | Imidazothiadiazole derivatives | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 2013-03-05 | — | — | US | disclosed |
| US-8389554-B2 | Imidazothiadiazole derivatives | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 2013-03-05 | — | — | US | disclosed |
| US-20110130396-A1 | IMIDAZOTHIADIAZOLE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2011-06-02 | — | — | US | disclosed |
| US-20110130396-A1 | IMIDAZOTHIADIAZOLE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2011-06-02 | — | — | US | disclosed |
| US-20110130396-A1 | IMIDAZOTHIADIAZOLE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2011-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110130396-A1 | IMIDAZOTHIADIAZOLE DERIVATIVES | TGFBR1, TGFBR2, IGF1R | FYN 1977/4885PIK3CG 1492/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.